Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
Abstract
Patients with chronic kidney disease often develop secondary hyperparathyroidism (SHPT), marked by high levels of circulating parathyroid hormone (PTH) and increased risk of morbidity and mortality. Patients with SHPT are treated with a therapeutic combination that commonly includes calcimimetics, which have recently become popular in clinical settings, and other agents such as vitamin D preparations. Calcimimetics are a drug class that reduces...
Paper Details
Title
Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
Published Date
Oct 23, 2019
Volume
24
Issue
3
Pages
248 - 257
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History